Company Filing History:
Years Active: 1979-1989
Title: Stig I Gustavsson: Innovator in Peptide Derivatives
Introduction
Stig I Gustavsson is a prominent inventor based in Mölndal, Sweden, known for his significant contributions to the field of medicinal chemistry. With a total of four patents to his name, Gustavsson has focused on developing innovative peptide derivatives that have important applications in medical treatments, particularly in the area of thrombosis.
Latest Patents
Gustavsson's latest patents include breakthrough work on new peptide derivatives, specifically tripeptide derivatives characterized by the general formula that inhibits thrombin. Notably, his patent on thrombin-inhibiting N-alpha-arylsulfonyl-p-guanidinophenylalanine amides presents a novel compound structure, where Ar is a substituted aryl, and R1 and R2 represent alkyl groups ranging from 1 to 5 carbon atoms. This innovation not only encompasses racemate forms but also optical active antipodes and their pharmaceutically acceptable salts. Additionally, these compounds are aimed at treating thrombosis and offer methods for determining thrombin concentration in blood.
Career Highlights
Throughout his career, Stig I Gustavsson has collaborated with reputable companies, such as Ab Kabi and Kabivitrum AB. His research has been pivotal in advancing pharmaceutical compositions and diagnostics that utilize his patented compounds for effective treatments.
Collaborations
Gustavsson has worked alongside esteemed colleagues, including Bo T Af Ekenstam and Leif E Aurell. These collaborations have fostered a productive environment for innovation in pharmaceutical research, further enhancing the impact of his inventions in the medical field.
Conclusion
Stig I Gustavsson exemplifies the dedication and ingenuity required to innovate in the competitive landscape of medicinal chemistry. His contributions to peptide derivatives and thrombin inhibition not only highlight his role as an inventor but also underscore the potential for these compounds to shape future therapeutic strategies against thrombosis. As he continues to explore new horizons in research, Gustavsson remains a vital figure in the domain of innovation.